Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 215 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Naproxen sodium Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Naproxen for Pain Control With Intrauterine Device Insertion

NCT02388191
View directory record Official record
Conditions
Contraception
Interventions
Naproxen sodium, Placebo tablet
Drug · Other
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years and older · Female only
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 3 Interventional

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches

NCT00434083
View directory record Official record
Conditions
Migraine Headaches
Interventions
sumatriptan, naproxen sodium
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 11, 2007 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

"Completeness of Response" Following Treatment With Treximet™ for Migraine

NCT00893737
View directory record Official record
Conditions
Migraine
Interventions
sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Francisco, California • Kalamazoo, Michigan • Springfield, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Sep 2, 2026, 7:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache

NCT01916395
View directory record Official record
Conditions
Migraine
Interventions
sumatriptan and Treximet
Drug
Lead sponsor
Gary E. Ruoff, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 4, 2013 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure

NCT00662610
View directory record Official record
Conditions
Osteoarthritis, Hypertension
Interventions
naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
29
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 2 Interventional Results available

Acetaminophen/Naproxen Sodium Dose Ranging Study

NCT04447040
View directory record Official record
Conditions
Pain
Interventions
Acetaminophen/naproxen sodium Dose A, Acetaminophen/naproxen sodium Dose B, Acetaminophen/naproxen sodium Dose C, Acetaminophen/naproxen sodium Dose D, Acetaminophen/naproxen sodium Dose E, Placebo
Drug
Lead sponsor
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Industry
Eligibility
17 Years to 50 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Not applicable Interventional

Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee

NCT00928837
View directory record Official record
Conditions
Osteoarthritis
Interventions
Flavocoxid 500 mg, Naproxen, Placebo, flavocoxid 250 mg
Dietary Supplement · Drug · Other
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
35 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

NCT00664560
View directory record Official record
Conditions
Osteoarthritis
Interventions
PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid
Drug
Lead sponsor
POZEN
Industry
Eligibility
50 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 3 Interventional Results available

TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine

NCT00385008
View directory record Official record
Conditions
Migraine Disorders
Interventions
Combination Product (sumatriptan succinate / naproxen sodium), RELPAX(eletriptan) 40mg Tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 2 Interventional

Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee

NCT01102660
View directory record Official record
Conditions
Osteoarthritis
Interventions
PH-797804, Placebo, Naproxen, Naproxen + PH-797804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Paramount, California • Spring Valley, California • Valley Village, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment

NCT02128490
View directory record Official record
Conditions
Gout, Moderate Renal Impairment
Interventions
Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
89
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 2, 2026, 7:09 AM EDT
Withdrawn Phase 4 Interventional

Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department

NCT02945839
View directory record Official record
Conditions
Migraine
Interventions
Preventative Medication (PM), Enhanced Usual Care, PMR (progressive muscle relaxation therapy)
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 4 Interventional Results available

Study to Collect Information on How Well the Study Drug Naproxen Sodium Tablets Works Compared to Hydrocodone/Acetaminophen Tablets in Order to Relieve Pain in Participants Experiencing Moderate to Severe Pain After Having Their Wisdom Teeth Removed

NCT04307940
View directory record Official record
Conditions
Pain
Interventions
Naproxen Sodium (Aleve, BAY117031), Hydrocodone/Acetaminophen, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 40 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

NCT00007189
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Naproxen Sodium (Aleve), Celecoxib (Celebrex)
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
70 Years and older
Enrollment
2,625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
6
States / cities
Sun City, Arizona • Tampa, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 2, 2026, 7:09 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Effects of Naproxen on Physical Performance

NCT00410995
View directory record Official record
Conditions
Healthy
Interventions
Naproxen
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 10, 2007 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 3 Interventional Results available

Migraine Study in Adolescent Patients

NCT00843024
View directory record Official record
Conditions
Migraine Disorders
Interventions
Sumatriptan and Naproxen Sodium, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 17 Years
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
79
States / cities
Gilbert, Arizona • Litchfield Park, Arizona • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

NCT03493945
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor, Non-metastatic Castration-resistant Prostate Cancer
Interventions
M7824, N-803, MVA-BN-Brachyury, FPV-Brachyury, Epacadostat, Acetaminophen, Ibuprofen, Naproxen, Benadryl, EKG, Bone scan, CT chest, abdomen and pelvis, MRI
Biological · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Acetaminophen/Naproxen Sodium Fixed Combination Tablets in Adolescents 12 to <17 Years of Age With Pain

NCT05844995
View directory record Official record
Conditions
Orthodontic Pain
Interventions
Acetaminophen/Naproxen Sodium
Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
12 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 4 Interventional Results available

Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine

NCT01300546
View directory record Official record
Conditions
Migraine
Interventions
Sumatriptan/Naproxen Sodium, Naproxen Sodium
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Newport Beach, California • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

NCT03161093
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Naproxen, Fasinumab-matching placebo, Naproxen-matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
58
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

NCT00367211
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
PN 200 tablets (500 mg naproxen and 20 mg omeprazole), Naproxen 500 mg tablets (PN 200 minus omeprazole)
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 4 Interventional Results available

Ictal and Interictal Inflammatory Markers in Migraine

NCT01138150
View directory record Official record
Conditions
Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 2, 2026, 7:09 AM EDT
Completed Phase 4 Interventional Results available

OTC Naproxen and Acetaminophen Anti-Inflammatory Action in Dental Implant Patients

NCT04694300
View directory record Official record
Conditions
Osseointegrated Dental Implantation, Pain, Acute
Interventions
Naproxen, Acetaminophen, Tramadol
Drug
Lead sponsor
Hersh, Elliot V., DMD, MS, PhD
Individual
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 2, 2026, 7:09 AM EDT
Terminated Phase 4 Interventional Results available

Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS

NCT04015596
View directory record Official record
Conditions
PANDAS, Anxiety Disorder, Autoimmune Diseases, Obsessive-Compulsive Disorder
Interventions
Naproxen Sodium, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 15 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 2, 2026, 7:09 AM EDT